Join
Live feed
·
PRReleasevia Quantisnow
TG Therapeutics Inc. logo

TG Therapeutics Announces Publication of Post-Hoc Data from the Phase 3 ULTIMATE I & II Trials in Treatment Naive Patients with Relapsing Forms of MS Published in Frontiers in Immunology

ByQuantisnow·Wall Street's wire, on your screen.
TGTX· TG Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track TGTX (TG Therapeutics Inc.) and more on Quantisnow.